ATE239471T1 - Kombination eines angiotensin-ii antagonistisch wirkendes benzimidazols mit ein diuretikum - Google Patents

Kombination eines angiotensin-ii antagonistisch wirkendes benzimidazols mit ein diuretikum

Info

Publication number
ATE239471T1
ATE239471T1 AT96115146T AT96115146T ATE239471T1 AT E239471 T1 ATE239471 T1 AT E239471T1 AT 96115146 T AT96115146 T AT 96115146T AT 96115146 T AT96115146 T AT 96115146T AT E239471 T1 ATE239471 T1 AT E239471T1
Authority
AT
Austria
Prior art keywords
sup
group
angiotensin
compound
combination
Prior art date
Application number
AT96115146T
Other languages
English (en)
Inventor
Yoshiyuki Inada
Keiji Kubo
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15153791&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE239471(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE239471T1 publication Critical patent/ATE239471T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT96115146T 1993-06-07 1994-06-07 Kombination eines angiotensin-ii antagonistisch wirkendes benzimidazols mit ein diuretikum ATE239471T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP13552493 1993-06-07

Publications (1)

Publication Number Publication Date
ATE239471T1 true ATE239471T1 (de) 2003-05-15

Family

ID=15153791

Family Applications (4)

Application Number Title Priority Date Filing Date
AT96115146T ATE239471T1 (de) 1993-06-07 1994-06-07 Kombination eines angiotensin-ii antagonistisch wirkendes benzimidazols mit ein diuretikum
AT03001570T ATE372116T1 (de) 1993-06-07 1994-06-07 Kombination von angiotensin-ii antagonistisch wirkenden benzimidazolen mit diuretika
AT94108687T ATE311188T1 (de) 1993-06-07 1994-06-07 Kombination eines angiotensin-ii antagonistisch wirkenden benzimidazols mit manidipin zur behandlung von bluthochdruck
AT03001569T ATE372115T1 (de) 1993-06-07 1994-06-07 Kombination eines angiotensin-ii antagonistisch wirkenden benzimidazols mit einem diuretikum

Family Applications After (3)

Application Number Title Priority Date Filing Date
AT03001570T ATE372116T1 (de) 1993-06-07 1994-06-07 Kombination von angiotensin-ii antagonistisch wirkenden benzimidazolen mit diuretika
AT94108687T ATE311188T1 (de) 1993-06-07 1994-06-07 Kombination eines angiotensin-ii antagonistisch wirkenden benzimidazols mit manidipin zur behandlung von bluthochdruck
AT03001569T ATE372115T1 (de) 1993-06-07 1994-06-07 Kombination eines angiotensin-ii antagonistisch wirkenden benzimidazols mit einem diuretikum

Country Status (9)

Country Link
EP (6) EP0753301B1 (de)
AT (4) ATE239471T1 (de)
CA (1) CA2125251C (de)
CY (1) CY2370B1 (de)
DE (4) DE69434560T2 (de)
DK (1) DK0753301T3 (de)
ES (1) ES2193217T3 (de)
PT (1) PT753301E (de)
SG (1) SG45336A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033456A2 (en) * 1994-06-07 1995-12-14 Telor Ophthalmic Pharmaceuticals, Inc. Reducing intraocular pressure using aryloxy- and aryl-acetic acids
US5763491A (en) * 1994-12-09 1998-06-09 The Regents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US6228873B1 (en) 1994-12-09 2001-05-08 The Regents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
EP1057479A1 (de) * 1994-12-14 2000-12-06 Enbalt Trading Limited Pharmazeutische Zubereitung zur Direktverpressung
KR19990022723A (ko) * 1995-06-07 1999-03-25 윌리암스 로저 에이 울혈성심부전의 치료를 위한 스피로노락톤 및 앤지오텐신 ii 길 항제 복합요법
AU725689B2 (en) * 1995-06-07 2000-10-19 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of congestive heart failure
WO1996040256A1 (en) * 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination of an angiotensin ii antagonist and spironolactone
EP0914158B2 (de) * 1996-04-05 2006-01-25 Takeda Chemical Industries, Ltd. Pharmazeutische kombination enthaltend einen wirkstoff mit angiotensin-ii antagonistischer aktivität und einen wirkstoff der die insulin-sensitivität erhöht
WO1999012534A1 (en) * 1997-09-10 1999-03-18 Ono Pharmaceutical Co., Ltd. Peroxisome proliferator-activated receptor controllers
TR200100062T2 (tr) * 1998-07-10 2001-06-21 Novartis Ag Valsartan ve kalsiyum kanalı bloklayıcısının anti-hipertensif kombinasyonu
TWI290470B (en) 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
AU2001227084A1 (en) * 2000-01-25 2001-08-07 Japan Tobacco Inc. N-arylhydrazide compounds and use thereof as drugs
CA2426674A1 (en) * 2000-10-25 2002-05-02 Takeda Chemical Industries, Ltd. Agent for preventing or treating portal hypertension
AU2002226365A1 (en) * 2000-12-01 2002-06-11 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
EP1452176A4 (de) * 2001-12-03 2009-01-21 Takeda Pharmaceutical Mittel zur verbesserung der insulinresistenz
CA2469616A1 (en) 2001-12-12 2003-06-19 James W. Aiken Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
KR20120058618A (ko) * 2003-01-31 2012-06-07 다이이찌 산쿄 가부시키가이샤 동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약
EP1628663B1 (de) 2003-05-15 2009-07-29 Roskamp Research llc Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid-neurotoxizität und mikrogliosis
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
NZ584729A (en) 2007-10-05 2012-12-21 Alzheimer S Inst Of America Inc Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer
AR072883A1 (es) * 2008-07-31 2010-09-29 Takeda Pharmaceutical COMPOSICIoN FARMACÉUTICA SoLIDA CON EL COMPUESTO (5-METIL-2-OXO-1,3-DIOXOL-4-IL)METIL2-ETOXI-1-{[2' -(5-OXO-4,5-DIHIDRO-1,2,4-OXADIAZOL-3-IL)BIFENIL-4-IL]METIL}-1H-BENCIMIDAZOL-7-CARBOXILATO Y UN DIURÉTICO PARA LA PROFILAXIS O TRATAMIENTO DE ENFERMEDADES DEL APARATO CIRCULATORIO.
UY32126A (es) 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
WO2010075347A2 (en) * 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
PE20120315A1 (es) * 2009-04-30 2012-04-07 Takeda Pharmaceutical Una composicion farmaceutica que comprende candesartan, candesartan cilexetil, o azilsartan, combinado con amlodipino
TR201004754A1 (tr) * 2010-06-11 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Yeni Farmasötik Kombinasyonlar
IN2014DN09045A (de) 2012-05-07 2015-05-22 Bayer Pharma AG

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0400835A1 (de) * 1989-05-15 1990-12-05 Merck & Co. Inc. Substituierte Benzimidazole als Angiotensin II-Hemmer
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
ES2121773T3 (es) * 1990-06-08 1998-12-16 Hoechst Marion Roussel Inc Derivados de bencimidazol, su procedimiento de preparacion, productos intermedios, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
KR100222252B1 (ko) * 1990-12-14 1999-10-01 스튜어트 알. 수터 안지오텐신 ii 수용체 차단 조성물
FR2673427B1 (fr) * 1991-03-01 1993-06-18 Sanofi Elf Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
TW300219B (de) * 1991-09-14 1997-03-11 Hoechst Ag
TW284688B (de) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
GB2270841A (en) * 1992-09-09 1994-03-30 Merck & Co Inc Compositions for Treating vascular restenosis
AU5449194A (en) * 1992-10-26 1994-05-24 Merck & Co., Inc. Combinations of angiotensin-ii receptor antagonists and diuretics
ATE300287T1 (de) * 1994-02-08 2005-08-15 Novartis Pharma Gmbh Behandlung von normaldruckglaukom mit valsartan

Also Published As

Publication number Publication date
CY2370B1 (en) 2004-06-04
EP0753301B1 (de) 2003-05-07
EP2277520A3 (de) 2011-08-24
DK0753301T3 (da) 2003-07-21
EP1306088A1 (de) 2003-05-02
CA2125251C (en) 2005-04-26
DE69434560D1 (de) 2006-01-05
EP1844774A3 (de) 2008-08-20
DE69432644T2 (de) 2003-11-27
EP0628313B1 (de) 2005-11-30
EP1844774A2 (de) 2007-10-17
ATE372116T1 (de) 2007-09-15
EP2277520A2 (de) 2011-01-26
CA2125251A1 (en) 1994-12-08
PT753301E (pt) 2003-08-29
DE69434560T2 (de) 2006-06-08
DE69435021D1 (de) 2007-10-18
EP1306089B1 (de) 2007-09-05
SG45336A1 (en) 1998-01-16
ES2193217T3 (es) 2003-11-01
ATE372115T1 (de) 2007-09-15
DE69435022T2 (de) 2008-05-29
EP0628313A1 (de) 1994-12-14
EP0753301A1 (de) 1997-01-15
DE69435021T2 (de) 2008-05-29
ATE311188T1 (de) 2005-12-15
DE69432644D1 (de) 2003-06-12
DE69435022D1 (de) 2007-10-18
EP1306088B1 (de) 2007-09-05
EP1306089A1 (de) 2003-05-02

Similar Documents

Publication Publication Date Title
ATE239471T1 (de) Kombination eines angiotensin-ii antagonistisch wirkendes benzimidazols mit ein diuretikum
ES2065182T3 (es) Derivados de fenilamidinas utiles como inhibidores de la agregacion de plaquetas.
ATE306261T1 (de) Antithrombosemittel
DK0934276T3 (da) Anthranilinsyrederivater som multiresistensmodulatorer
MA27664A1 (fr) Acides gras a chaine moyenne, glycerides et analogues utilises en tant que stimulateurs de l'erythropoiese
ATE170845T1 (de) Plättchenaggregationsinhibitoren
ATE227293T1 (de) 2,3-disubstituierte-(5,6)-heteroarylkondensiert - pyrimidin-4-one
ATE142641T1 (de) Neue peptid-verbindungen und verfahren zur herstellung davon
GR3033862T3 (en) Angiotensin ii antagonists as a prophylactic or therapeutic drug for renal diseases.
FI935800A0 (fi) Antidepressiva och mot Parkisons sjukdom verksamma foereningar
ES2110115T3 (es) Inhibidores de la agregacion de plaquetas.
EP1329218A4 (de) Wirkstoffe zur vorbeugung und behandlung portaler hypertonie
RU94046387A (ru) Производные пиримидина, способ их получения, фармацевтическая композиция, ее применение и промежуточные продукты
KR970703301A (ko) 신규 디아미노메틸리덴 유도체(novel diamincmethylidene derivative)
NO934760L (no) Arylsubstituerte heterosykliske forbindelser
MX9300306A (es) Bencimidazoles medicamentos que contienen estos compuestos y procedimiento para su preparacion.
DK0604355T3 (da) Arylsubstituerede heterocykliske forbindelser
ATE109485T1 (de) Derivate von n-(vincristinyl-23) und n- (noranhydro-5-vinblastinyl-23) von amino-1- methylphosphonsäure, ihre verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ES2181879T3 (es) Inhibidores de la agkytubacuib de las plaquetas que contienen restos de aminoacidos con cadenas laterales de c-terminal aminergicos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0753301

Country of ref document: EP